Trials / Completed
CompletedNCT02201030
Immunogenicity and Safety Study of NBP606 in Healthy Infants
Multi-Center, Randomized, Double-Blind, Phase III Trial to Assess the Immunogenicity and Safety of Primary Vaccination With NBP606 in Healthy Infants
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 577 (actual)
- Sponsor
- SK Chemicals Co., Ltd. · Industry
- Sex
- All
- Age
- 42 Days – 98 Days
- Healthy volunteers
- Accepted
Summary
This study will assess the immunogenicity and safety of primary vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NBP606 | A single intramuscular injection into the thigh |
| BIOLOGICAL | Prevnar13 | A single intramuscular injection into the thigh |
Timeline
- Start date
- 2014-09-06
- Primary completion
- 2016-10-21
- Completion
- 2016-10-21
- First posted
- 2014-07-25
- Last updated
- 2020-04-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02201030. Inclusion in this directory is not an endorsement.